A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors

Summary

This clinical trial tests a collaborative pain management intervention (ASCENT) for improving cancer pain in cancer survivors. Cancer pain is prevalent, under-treated, and remains a major cause of suffering, impairment, and disability for millions of Americans. Individual pain interventions and care models show promise for cancer pain in controlled settings. All cancer survivors stand to benefit from electronic health record innovations, as they can experience profound pain outcomes, including marked under- and over-prescribing of opioids. Digitally facilitated solutions are especially helpful and can be customized to address patient needs. The ASCENT intervention provides patients with an educational guide that describes techniques for addressing cancer pain, and uses community health workers and pain care managers to coach patients through a personalized pain management plan. This study may help researchers learn how pain management strategies can improve cancer pain and lower risk of opioid exposure and dependency in cancer survivors.

Conditions

• Hematopoietic and Lymphoid System Neoplasm
• Malignant Solid Neoplasm
• Hematopoietic and Lymphatic System Neoplasm

Interventions

OTHER

Best Practice

Receive enhanced usual care

OTHER

Educational Intervention

Receive ASCENT guide

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Electronic Health Record Review

Ancillary studies

PROCEDURE

Health Telemonitoring

Attend video or phone calls with a CHW and/or PCM

BEHAVIORAL

Cancer Pain Management

Receive personalized pain management plan

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Mayo Clinic

  lead OTHER

Principal Investigators

• Andrea L. Cheville, M.D. · Mayo Clinic in Rochester

Study Design

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-02-07

Primary Completion

2027-01-31

Completion

2027-08-31

Countries

• United States

Study Locations